April 8, 2021

Press release

FluoGuide has received green light to proceed to fifth dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma

Copenhagen, Denmark, 8 April 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee... [Read more]

February 3, 2021

Press release

FluoGuide plans to change listing venue from Spotlight to Nasdaq First North Sweden and publishes Company Description

Copenhagen, Denmark, 3 February 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today announced that the Company has applied for admission... [Read more]

February 2, 2021

Press release

FluoGuide annonces publication of two patent applications covering the company’s uPAR technology platform for improving surgery

Copenhagen, Denmark, 2 February 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) announces that two new patent applications, covering the use... [Read more]

January 26, 2021

Press release

FluoGuide A/S publishes annual report for the fiscal year 2020

Copenhagen, Denmark, 26 January 2021  – FluoGuide A/S (“FluoGuide” or the “Company”) hereby publishes its annual report for the fiscal year... [Read more]

January 26, 2021

Press release

FluoGuide A/S publishes Year-end report for 2020

Copenhagen, Denmark, 26 January 2021  – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January... [Read more]

January 25, 2021

Press release

Ordinary General Meeting

Copenhagen, Denmark, 25 January 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) hereby convenes an ordinary general meeting to be held... [Read more]

January 25, 2021

Press release

Change in the Board of Directors of FluoGuide

Copenhagen, Denmark, 25 January 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) announces that the chairman of the Board of Directors,... [Read more]

January 20, 2021

Press release

Financial calendar for 2021

Copenhagen, Denmark, 20 January 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) releases financial calendar for 2021. Please note that the... [Read more]

January 13, 2021

Press release

FluoGuide gets green light to proceed to third dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma

Copenhagen, Denmark, 13 January 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee... [Read more]